Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.

ABSTRACT:

Purpose

To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics and clinical wound healing outcomes.

Experimental design

Before tumor resection, three doses of bevacizumab (15 mg/kg) were administered to patients (median age, 12.2 years) enrolled in a multi-institutional osteosarcoma trial. Serial sampling for bevacizumab pharmacokinetics was obtained from 27 patients. A population pharmacokinetic model was fit to the data, and patient demographics and clinical chemistry values were systematically tested as predictive covariates on model parameters. Associations between bevacizumab exposure and wound healing status were evaluated by logistic regression.

Results

Beva

SUBMITTER: Turner DC 

PROVIDER: S-EPMC4024352 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature